This latest collaboration seeks synergistic methodologies that will enable the earliest, best predictions of lung cancer May 18, 2023. SAN DIEGO, Calif.– Micronoma announced today that it is serving as the industry partner on a grant the NYU Grossman School of...
Micronoma’s microbiome platform is breaking into its next phase with validation from the U.S. Food and Drug Administration. Last month, the San Diego-based company announced that the FDA has given its OncobiotaLUNG assay Breakthrough Device Designation. The...
The FDA has granted breakthrough device designation to the novel, microbiome-driven, liquid biopsy assay OncobiotaLUNG for the detection of lung carcinomas, according to a press release from developer Micronoma.1 The assay is one of the first blood microbiome–driven...
The FDA has granted the OncobiotaLUNG assay a breakthrough device designation for the early detection of lung cancer. The FDA has provided the OncobiotaLUNG assay a breakthrough device designation, according to the device maker, Micronoma.1 The OncobiotaLUNG assay is...
Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA). As a...
